Publication of insider information pursuant to Art. 17 MAR

Jena, Germany | April 15, 2025 | Carl Zeiss Meditec AG

In the second quarter of fiscal year 2024/25 ending March 31, 2025, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of around EUR 560 million (previous year: EUR 472.1 million), based on preliminary data, an increase of around 19%. This includes a contribution of around EUR 54 million from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), which has been consolidated for the first time since April 2024. Excluding this contribution, revenue growth would have amounted to around 7%. Earnings before interest, taxes and amortization on intangible assets from purchase price allocations (EBITA) reached around EUR 78 million (previous year: EUR 67.2 million). Earnings per share resulted in EUR 0.52 (previous year: EUR 0.52).

The increase in revenue and earnings in the second quarter of 2024/25 has been driven in particular by stronger than previously anticipated growth in the consumables business for refractive surgery in China.

After 6 months 2024/25, revenue reached around EUR 1,050 million (previous year: EUR 947.2 million) and EBITA reached EUR 114 million (previous year: EUR 113.2 million). Earnings per share came in at EUR 0.70 (previous year: EUR 0.94).

For fiscal year 2024/25, Carl Zeiss Meditec AG expects moderate revenue growth (against a previous year’s base of EUR 2,066.1 million) as well as a stable to slightly higher EBITA (against a previous year’s base of EUR 248.9 million). In light of current macro-economic and geopolitical uncertainties regarding the introduction of trade tariffs by the United States of America and incremental currency risks a more precise update to the forecast cannot currently be provided.

The half year report 2024/25 will be published on May 13, 2025.